Additionally, one patient who was included in the graph as a VGPR converted to a CR. Taken together, these data show, in fact, that cemsidomide plus dexamethasone has a class-leading anti-myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback